DOCSLIB.ORG

Performance Characteristics of Adenoid Cystic Carcinoma of The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Performance Characteristics of Adenoid Cystic Carcinoma of The Letters to the Editor Many salivary gland neoplasms con- Medical City, Abu Dhabi, United Arab Performance tain both stroma and epithelial and Emirates Characteristics of myoepithelial cells, which have differ- ent and variable characteristics with 1. Tabatabai ZL, Auger M, Kurtycz DF, et al. Adenoid Cystic Performance characteristics of adenoid cystic carci- different stains. In addition, the spatial noma of the salivary glands in fine-needle aspirates: Carcinoma of the Salivary relationship between the stroma and results from the College of American Pathologists the cells is of importance in different Nongynecologic Cytology Program. Arch Pathol Glands in Fine-Needle Lab Med. 2015;139(12):1525–1530. doi:10.5858/ salivary gland tumors. Therefore, we arpa.2013-0173-CP. Aspirates strongly believe that these issues play 2. Kopec´ T, Mikaszewski B, Jackowska J, Was´- aroleininflatingthedegreeof niewska-Okupniak E, Szyfter W, Wierzbicka M. Treatment of parotid malignancies—10 years of misinterpretation at both ends of the experience. J Oral Maxillofac Surg. 2015;73(7): spectrum (both false negatives and 1397–1402. doi:10.1016/j.joms.2014.12.036. To the Editor.—We read with depth false positives). We are quite sure that 3. Bruzgielewicz A, Osuch-Wojcikiewicz´ E, and interest the article by Tabatabai et the authors are aware of these limita- Majszyk D, et al. Adenoid cystic carcinoma of the 1 head and neck—a 10 years experience [in Polish]. al addressing the performance char- tions but we were compelled to raise Otolaryngol Pol. 2011;65(5 suppl):6–11. acteristics of adenoid cystic carcinoma these important points in this letter to 4. Ellington CL, Goodman M, Kono SA, et al. (ACC) of the salivary glands in fine- the editor for a couple of important Adenoid cystic carcinoma of the head and neck: needle aspirates, resulting from the incidence and survival trends based on 1973-2007 reasons. First, we are afraid that such a Surveillance, Epidemiology, and End Results data College of American Pathologists high number of errors may cause fear [erratum in Cancer. 2012;118(21):5448–5449]. Nongynecologic Cytology Program. and intimidation among pathologists Cancer. 2012;118(18):4444–4451. doi:10.1002/ The authors elegantly described and cncr.27408. to the point of discouragement in their 5. Al-Abbadi MA. Pitfalls in salivary gland fine- documented the statistical perfor- attempts to interpret salivary gland needle aspiration cytology [author reply in Arch mance regarding these ACCs during cytology. Second, the notion that fine- Pathol Lab Med. 2006;130(10):1428]. Arch Pathol a 10-year period. As described by the Lab Med. 2006;130(10):1428. needle aspiration is the recommended 6. Hughes JH, Volk EE, Wilbur DC; Cytopathology authors, this important and valuable initial diagnostic tool for salivary gland Resource Committee, College of American Pathol- educational program is performed and lesions may be affected, consequently ogists. Pitfalls in salivary gland fine-needle aspira- managed by our association, the Col- tion cytology: lessons from the College of American pushing our clinician colleagues to Pathologists Interlaboratory Comparison Program in lege of American Pathologists (CAP). avoid using this approach as the Nongynecologic Cytology. Arch Pathol Lab Med. The CAP staff and the scientific preferred preoperative diagnostic tool. 2005;129(1):26–31. committee have to be commended Third, making a specific preoperative on their efforts to help raise the diagnosis of ACC based on the cytol- The authors have no relevant financial standard of care for our profession. ogy of a salivary gland mass is interest in the products or companies However, as mentioned briefly by extremely critical for the treating described in this article. the authors in the Material and surgeon. There is a need not only for Methods and Comment sections, this differentiating ACC from other benign doi: 10.5858/arpa.2016-0138-LE Nongynecologic Cytology Program is mimickers such as pleomorphic ade- carried out by sending 1 slide, together noma, but also for differentiating ACC with a brief history of the patient, to from other malignancies, as this will participants. Consequently, it is re- be helpful to the surgeon, who will quired that participating institutions, approach ACC differently from other pathologists, and cytotechnologists carcinomas such as low- to interme- evaluate the slide and render an diate-grade mucoepidermoid carcino- In Reply.—We thank Dr Al-Abbadi opinion on a general categorization ma and basaloid adenocarcinoma. and Dr Aziz for their interest in our and then try to give a specific inter- Surgical excision of ACC is more article,1 for their thoughtful com- pretation. Despite the fact that these radical than that of other carcinomas; ments, and for highlighting the limi- slides are thoroughly evaluated by the and ear, nose, and throat oncologic tations of the study. We do point out committeetomakesurethatthe surgeons would prefer that an accurate in our article that the lower sensitivity cytologic features are clear and inter- diagnosis of ACC be made preopera- in our data may be due to the fact that pretable, this educational exercise is tively.2–4 The latter point was not well our study is based on a single-slide very far from the usual and routine emphasized by the authors and we interpretation and that this setting practice that we all follow. As we all certainly hope that this letter may be probably does not truly mimic the know, fine-needle aspiration of sali- of value in addressing this issue. actual practice of cytology, where vary gland lesions has certain pecu- Lastly, similar issues were raised in a more clinical and radiologic informa- liarities and deserves close attention. It previous letter5 in 2006 addressing tion may be available and where is highly recommended by experts in similar shortcomings of the CAP interpretation is usually made on the field that interpretation of salivary program; these were reported by several slides, including various and gland aspirates be made with extreme Hughes et al.6 complimentary preparation types such caution, taking into consideration the as Papanicolaou- and modified Giem- clinical and radiologic data and the Mousa A. Al-Abbadi, MD1;Luaay sa–stained slides, and possibly cell patients’ symptoms during the aspira- Aziz, MD2 block and/or ancillary testing. The tion process, and most importantly, intention of our article certainly was thoroughly evaluating multiple slides 1 Departments of Pathology & Labo- not to discourage the use or perfor- and smears with Diff-Quik, Papanico- ratory Medicine, and 2 ENT and Head mance of fine-needle aspirations laou, and hematoxylin-eosin stains. and Neck Surgery, Sheikh Khalifa (FNAs) in the evaluation of salivary Arch Pathol Lab Med—Vol 140, November 2016 Letters to the Editor 1183 Letters to the Editor gland lesions, but rather to (1) em- The authors have no relevant financial data reveal a similar trend in Oncotype phasize that when presented with interest in the products or companies DX RS among breast cancer histologic excellent diagnostic material our par- described in this article. subtypes: The 2 most common were ticipants were able to provide concor- invasive ductal carcinoma of no special dant diagnoses, (2) present a review of doi: 10.5858/arpa.2016-0334-LE type (IDC, n ¼ 228) with an average RS cytomorphologic characteristics of ad- of 17 6 9.5, followed by invasive lobular enoid cystic carcinoma, and (3) point carcinoma (ILC, n¼51) with a mean RS out that even in particularly difficult To Oncotype or Not: of 16.6 6 6.9 (Table 1). Other subtypes cases of adenoid cystic carcinoma included mixed invasive ductal and where basaloid features are evident Knowledge of Histologic lobular carcinoma (ID&LC), mucinous and predominate but the stromal Grade and Subtype May carcinoma (MC), mixed ductal and component is scant to absent on mucinous carcinoma (ID&MC), and FNA material, a descriptive diagnosis Help invasive carcinoma with micropapillary of salivary gland neoplasm with basa- component (ICMP). Recurrence scores loid features, in the appropriate clin- in 2 cases of tubular carcinoma (TC) ical and imaging context and with were 12 and 18; the RS in 1 case of clinical symptoms consistent with To the Editor.—We read with great 1 carcinoma with medullary features was perineural involvement, can be fol- interest the article by Bomeisl et al regarding Oncotype DX recurrence 63 (high risk). lowed up with appropriate surgical Among 68 of 328 histologic grade management. scores (RS) among histologic types of 1tumors(20.7%),44(64.7%)were We recognize and tend to point breast carcinoma. This brief report of classified as low risk and 24 (35.3%) out in similar papers from this Oncotype DX test results offers a were predicted as intermediate risk group2 that our situation, a profi- comparison with their results in a larger cohort. We reviewed all (n ¼ 328) for recurrence (Tables 2 and 3); there ciency-testing environment, is very Oncotype DX tests (Genomic Health were no high-risk grade 1 tumors in different from a clinical day-to-day Inc, Redwood City, California) request- our cohort. The pattern of RS in the working environment. The fact that ed at our institute from 2011–2015; our 2 histologic subtype–based prognosis cytologists can make the diagnosis when good material is available for evaluation should only encourage Table 1. Average Recurrence Score and Patient Age in Different Histologic the acquisition of and improve the Subtypes nature of such samples. We also Recurrence Recurrence encourage development of standards Histologic Total No. Score, Score, Patient Age, Patient Age, such as the proposed Milan System Subtype (% of Total) Mean (SD) Range Mean (SD), y Range, y for Salivary Gland Cytopathology, Invasive ductal 228 (69.5) 17 (9.5) 0–55 54.4 (9.4) 28–78 which can help to bring coherence carcinoma to the field and can improve utility of Invasive lobular 51 (15.5) 16.6 (6.9) 3–47 57 (9.6) 30–74 salivary gland FNA cytology and, carcinoma Mixed invasive 20 (6.1) 15.4 (9.0) 5–47 56.5 (9.9) 42–71 thus, patient care.
Load more

Recommended publications
  • Rare Presentation of Metastatic Lobular Breast Carcinoma Involving Clear Cell Renal Cell Carcinoma
    Hindawi Case Reports in Oncological Medicine Volume 2020, Article ID 5315178, 5 pages https://doi.org/10.1155/2020/5315178 Case Report Rare Presentation of Metastatic Lobular Breast Carcinoma Involving Clear Cell Renal Cell Carcinoma Dayne Ashman,1 Gabriela Quiroga-Garza,1 and Daniel Lee 2 1Department of Pathology, University of Pittsburgh, 5230 Centre Avenue, Pittsburgh, PA 15232, USA 2Department of Medicine, University of Pittsburgh, 5150 Centre Avenue, Pittsburgh, PA 15232, USA Correspondence should be addressed to Daniel Lee; [email protected] Received 23 March 2020; Accepted 3 September 2020; Published 15 September 2020 Academic Editor: Raffaele Palmirotta Copyright © 2020 Dayne Ashman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Although the first case of tumor-to-tumor metastasis was reported over a century ago, it remains a rare occurrence. We report a rare case of metastatic infiltrating lobular carcinoma involving clear cell renal cell carcinoma, as well as offer a brief literature review. 1. Introduction Microscopic examination of the biopsy specimen revealed two distinct neoplasms (Figure 3). The first neo- The phenomenon of one malignant tumor metastasizing to plasm identified demonstrated cells arranged in nests and another, unrelated, primary tumor, has been termed solid sheets with delicate vasculature. Cytologically, these “tumor-to-tumor” metastasis (TTM); it is a rare occurrence. neoplastic cells demonstrated clear cytoplasm with round To date, there have been fewer than 200 cases reported in nuclei and inconspicuous nucleoli, morphologically consis- the English literature.
    [Show full text]
  • Activity of Larotrectinib, a Highly Selective Inhibitor of Tropomyosin
    Activity of larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase, in TRK fusion breast cancers Funda Meric-Bernstam,1 Neerav Shukla,2 Nir Peled,3,4 Yosef Landman,3 Adedayo A. Onitilo,5 Sandra Montez,1 Nora C Ku,6 David M. Hyman,2 Alexander Drilon,2 David S. Hong1 1The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; 2Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA; 3Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel; 4Soroka Cancer Institute, Ben Gurion University, Beer Sheva, Israel; 5Marshfield Clinic Weston Center, Weston, Wisconsin, USA;6 Loxo Oncology, Inc., South San Francisco, California, USA San Antonio Breast Cancer Symposium® - December 4-8, 2018 Introduction Table 1: Adverse events with larotrectinib seen in ≥15% of patients Patient case studies Patient 3: ETV6-NTRK3 secretory breast cancer Patient 5: ETV6-NTRK3 secretory breast cancer (n=207)4 ■■ The family of tropomyosin receptor kinases (TRK), TRKA, B, and C are encoded by three distinct genes, NTRK1, 2, and 31 Treatment-emergent AEs (%) Treatment-related AEs (%) Patient 1: TPM3-NTRK1 invasive ductal carcinoma of the breast Baseline Day 54 Baseline Cycle 17, day 27 ■■ After embryogenesis, TRK proteins are primarily restricted to the nervous system and function during Grade 1 Grade 2 Grade 3 Grade 4 Total Grade 3 Grade 4 Total normal neuronal development and maintenance2–5 ■■ 34-year-old female diagnosed with invasive ductal carcinoma with metastasis
    [Show full text]
  • 1 Effective January 1, 2018 ICD‐O‐3 Codes, Behaviors and Terms Are Site‐Specific Alpha Order Last Updat
    Effective January 1, 2018 ICD‐O‐3 codes, behaviors and terms are site‐specific Alpha Order Last updated 8/22/18 Status ICD‐O‐3 Term Reportable Comments Morphology Y/N Code New Term 8551/3 Acinar adenocarcinoma (C34. _) Y Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3 New Term 8140/3 Acinar adenocarcinoma (C61.9 ONLY) Y For prostate only, do not use 8550/3 New Term 8572/3 Acinar adenocarcinoma, sarcomatoid (C61.9) Y New Term 8550/3 Acinar cell carcinoma Y Excludes C61.9‐ see 8140/3 New Term 8316/3 Acquired cystic disease‐associated renal cell carcinoma (RCC) Y (C64.9) New 8158/1 ACTH‐producing tumor N code/term New Term 8574/3 Adenocarcinoma admixed with neuroendocrine carcinoma (C53. _) Y Behavior 8253/2 Adenocarcinoma in situ, mucinous (C34. _) Y Important note: lung Code/term primaries ONLY: For cases diagnosed 1/1/2018 forward do not use code 8480 (mucinous adenocarcinoma) for in‐ situ adenocarcinoma, mucinous or invasive mucinous adenocarcinoma. 1 Status ICD‐O‐3 Term Reportable Comments Morphology Y/N Code Behavior 8250/2 Adenocarcinoma in situ, non‐mucinous (C34. _) Y code/term New Term 9110/3 Adenocarcinoma of rete ovarii (C56.9) Y New 8163/3 Adenocarcinoma, pancreatobiliary‐type (C24.1) Y Cases diagnosed prior to code/term 1/1/2018 use code 8255/3 Behavior 8983/3 Adenomyoepithelioma with carcinoma (C50. _) Y Code/term New Term 8620/3 Adult granulosa cell tumor (C56.9 ONLY) N Not reportable for 2018 cases New Term 9401/3 Anaplastic astrocytoma, IDH‐mutant (C71.
    [Show full text]
  • Nipple-Areolar Complex:Diagnostic Challenges
    Nipple-areolar complex:diagnostic challenges. Poster No.: C-1547 Congress: ECR 2014 Type: Educational Exhibit Authors: S. Manso Garcia1, S. Plaza Loma2, Y. Rodríguez de Diego1, V. Zurdo de Pedro1, R. Pintado Garrido1, E. Villacastin Ruiz1, M. Moya de la Calle1, M. J. Velasco Marcos1, H. Calero1; 1Valladolid/ ES, 2Valladolid, VA/ES Keywords: Inflammation, Hyperplasia / Hypertrophy, Biopsy, Ultrasound, Mammography, Breast DOI: 10.1594/ecr2014/C-1547 Any information contained in this pdf file is automatically generated from digital material submitted to EPOS by third parties in the form of scientific presentations. References to any names, marks, products, or services of third parties or hypertext links to third- party sites or information are provided solely as a convenience to you and do not in any way constitute or imply ECR's endorsement, sponsorship or recommendation of the third party, information, product or service. ECR is not responsible for the content of these pages and does not make any representations regarding the content or accuracy of material in this file. As per copyright regulations, any unauthorised use of the material or parts thereof as well as commercial reproduction or multiple distribution by any traditional or electronically based reproduction/publication method ist strictly prohibited. You agree to defend, indemnify, and hold ECR harmless from and against any and all claims, damages, costs, and expenses, including attorneys' fees, arising from or related to your use of these pages. Please note: Links to movies, ppt slideshows and any other multimedia files are not available in the pdf version of presentations. www.myESR.org Page 1 of 12 Learning objectives We describe normal anatomy and clinical and radiological findings of nipple-aerolar complex (NAC) disorders.
    [Show full text]
  • 2018 SEER Solid Tumor Manual
    4/6/2018 Eight Groups are Revised for 2018 Head & Neck Colon (includes rectosigmoid and rectum for cases diagnosed 1/1/2018 forward) 2018 SEER Lung (2018 Draft not yet available) Breast Solid Tumor Manual Kidney Urinary Sites (2018 Draft not yet available) 2018 KCR SPRING TRAINING Non‐malignant CNS (2018 Draft not yet available) Malignant CNS and Peripheral Nerves (2018 Draft not yet available) 2019 Changes for other two Groups Solid Tumor Rules What we will cover: ◦ Overview of General rules Cutaneous melanoma (minor revisions and draft available now) • Cutaneous melanoma site rules will be revised for 2019 implementation to incorporate ◦ New Head and Neck rules information from the new WHO 4th Ed Tumors of Skin scheduled to be released in 2018. ◦ New Colorectal rules ◦ New Breast rules Other sites (minor revisions and draft available now) ◦ New Kidney rules • Primary sites excluded are: •Rectosigmoid and rectum which are included in 2018 Colon rules. •Peripheral nerves which are included in 2018 Malignant Brain rules. •Other sites rules will be revised for 2019 implementation. The Solid Tumor Task Force has identified Remember: These are currently in draft form and may change slightly in the final version! the need to expand the rules to include GYN, soft tissue, thyroid and other site‐specific solid tumors. NEW! Code subtypes/variants when definitively described (with no modifiers) General Instructions Example: Well ‐differentiated neuroendocrine tumor 8240. Do not code a histology (*including subtypes or variants) when described as below: The 2018 solid tumor rules replace all previous MP/H rules, but they are effective for diagnoses on or after 1/1/2018.
    [Show full text]
  • The Pathology of Breast Cancer - Ali Fouad El Hindawi
    MEDICAL SCIENCES – Vol.I -The Pathology of Breast Cancer - Ali Fouad El Hindawi THE PATHOLOGY OF BREAST CANCER Ali Fouad El Hindawi Cairo University. Kasr El Ainy Hospital. Egypt. Keywords: breast cancer, breast lumps, mammary carcinoma, immunohistochemistry Contents 1. Introduction 2. Types of breast lumps 3. Breast carcinoma 3.1 In Situ Carcinoma of the Mammary Gland 3.1.1 Lobular Neoplasia (LN) 3.1.2 Duct Carcinoma in Situ (DCIS) 3.2 Invasive Carcinoma of the Mammary Gland 3.2.1 Microinvasive Carcinoma of the Mammary Gland 3.2.2 Invasive Lobular Carcinoma (ILC) 3.2.3 Invasive Duct Carcinoma 3.3 Paget’s disease of the Nipple 3.4 Bilateral Breast Carcinoma 4. Conclusions Glossary Bibliography Summary Breast cancer is the most common cancer in females. It may have strong family history (genetically related). It most commonly arises from breast ducts and less frequently from lobules. Since mammary carcinoma is the most common form of breast malignancy and one of the most common human cancers, most of this chapter is concentrated on the differential diagnosis of breast carcinoma 1. Introduction In clinicalUNESCO practice, a breast lump is very common.– EOLSS It may be accompanied in some cases by other patient’s complaints such as pain and/ or nipple discharge, which may be bloody. Sometimes more than one lump is detected in the same breast, or in both breasts. Cutaneous manifestations asSAMPLE nipple retraction, nipple and/ orCHAPTERS skin erosion, skin dimpling, erythema and peau d’ orange may also be noted; both by the patient and her physician. A lump may not be palpable in spite of breast symptoms such as pain and or nipple discharge.
    [Show full text]
  • Renal Mass in a Patient with Invasive Lobular Adenocarcinoma
    132 Renal mass in a patient with invasive lobular adenocarcinoma X. Mortiers, MD1, H. Vandeursen, MD, PhD2, T. Adams, MD2, T. Van den Mooter, MD3 SUMMARY Breast cancer often metastasises to bone, lymph nodes, liver and lung. In this case report, we present a 75-year-old woman with a suspicious mammography and ultrasound of the breast who had a synchronous painless renal lesion. On computed tomography, the renal mass was suspected of being a primary lesion of the renal pelvis, but anatomopathological examination of the nephro-ureterectomy specimen revealed that it was a metastatic deposit of invasive lobular adenocarcinoma of the breast. (BELG J MED ONCOL 2019;13(4):132-134) INTRODUCTION breast. A mammography and ultrasound were performed Breast cancer is the most frequent cancer in women, with and showed a retroareolar lobulated and dense, though not worldwide an estimated two million new cases each year, well delineated, structure with a spicular appearance, mul- and is currently the second most frequent cause of cancer tiple pathological vessels and enlarged axillary lymph nodes. death.1,2 This type of cancer has a five-year overall relative A biopsy of the lesion in the right breast showed the presence survival rate of 90.4%.3 The Belgian screening program of an invasive lobular adenocarcinoma, moderately differen- with mammography has increased the number of patients tiated (E-Cadherin negative, oestrogen receptor [ER]-posi- with breast cancers being diagnosed in an early setting. A tive, progesterone receptor [PR]-negative, human epidermal minority of patients with breast cancer is diagnosed with growth factor receptor 2 [HER2 negative]).
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • Conversion of Morphology of ICD-O-2 to ICD-O-3
    NATIONAL INSTITUTES OF HEALTH National Cancer Institute to Neoplasms CONVERSION of NEOPLASMS BY TOPOGRAPHY AND MORPHOLOGY from the INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY, SECOND EDITION to INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY, THIRD EDITION Edited by: Constance Percy, April Fritz and Lynn Ries Cancer Statistics Branch, Division of Cancer Control and Population Sciences Surveillance, Epidemiology and End Results Program National Cancer Institute Effective for cases diagnosed on or after January 1, 2001 TABLE OF CONTENTS Introduction .......................................... 1 Morphology Table ..................................... 7 INTRODUCTION The International Classification of Diseases for Oncology, Third Edition1 (ICD-O-3) was published by the World Health Organization (WHO) in 2000 and is to be used for coding neoplasms diagnosed on or after January 1, 2001 in the United States. This is a complete revision of the Second Edition of the International Classification of Diseases for Oncology2 (ICD-O-2), which was used between 1992 and 2000. The topography section is based on the Neoplasm chapter of the current revision of the International Classification of Diseases (ICD), Tenth Revision, just as the ICD-O-2 topography was. There is no change in this Topography section. The morphology section of ICD-O-3 has been updated to include contemporary terminology. For example, the non-Hodgkin lymphoma section is now based on the World Health Organization Classification of Hematopoietic Neoplasms3. In the process of revising the morphology section, a Field Trial version was published and tested in both the United States and Europe. Epidemiologists, statisticians, and oncologists, as well as cancer registrars, are interested in studying trends in both incidence and mortality.
    [Show full text]
  • SG Jordan MD and SB O'connor MD Departments of Radiology And
    World Health Organization 5thed Classification of Tumours of the Breast SG Jordan MD and SB O’Connor MD Departments of Radiology and Pathology and Laboratory Medicine Introduction Invasive Breast Carcinoma (IBC) Fibroepithelial tumours and hamartomas Genetic tumour syndromes The World Health Organization (WHO) establishes the standard Breast Cancer 2019 Fibroadenoma NEW! in this WHO edition for histopathologic diagnoses, defining diagnoses on a per organ Phyllodes tumour: Benign, Borderline, Malignant system basis. Estimated new cases and deaths from breast cancer in the US Hamartoma is a section delineating the familial predisposition to breast cancer, specifically the established and The most recent classification of breast tumors is the 5th edition New cases: 268,600 15.2 % of all new cancer cases emergent genes that are a source of discussion. published in November 2019. The publication reflects the views Deaths: 41,760 6.9 % of all cancer deaths BRCA1 and BRCA2 are well-established, and of the WHO Classification of Tumours Editorial Board that increasingly PALB2, as important predisposition convened at MD Anderson Cancer Center, Houston, USA Invasive Breast Carcinoma (IBC) refers to a large and heterogeneous group of malignant genes that merit testing in all patients with suspicion December 9-11, 2018. 153 authors from 21 countries epithelial neoplasms of breast glandular elements. IBCs are classified by morphology of familial predisposition. Many other genes (two contributed. The end result is an authoritative reference book (below). All IBCs are grouped into biomarker-defined subtypes for treatment, based on examples are ATM, CHEK2) have been identified in that serves as the international standard for oncologists and estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2).
    [Show full text]
  • Gastric Outlet Obstruction As the Presenting Manifestation of Metastatic Lobular Breast Carcinoma
    CASE REPORT Gastric Outlet Obstruction as the Presenting Manifestation of Metastatic Lobular Breast Carcinoma 1 1 Hien Nguyen, MD Department of Internal Medicine, Kaiser Permanente, Temple Hills, Maryland. 2 Connie Le, MD 2 3 Internal Medicine, Fairfax Hospital, Fairfax, Virginia. Hanh Nguyen, MD 4 3 Arman Moshyedi, MD Family Medicine, University of California Irvine, Irvine, California. 4 Department of Radiology, Holy Cross Hospital, Silver Spring, Maryland. Journal of Hospital Medicine 2009;4:E23–E24. VC 2009 Society of Hospital Medicine. KEYWORDS: acute abdominal emergencies, complications of cancer, diagnostic decision making. Gastric outlet obstruction (GOO) is frequently a diagnostic With the persistence of intractable vomiting, abdominal dilemma as malignancies have surpassed benign diseases as and pelvic CT scans were repeated and revealed duodenal etiologies of GOO.1,2 A case is presented of a previously thickening and luminal narrowing. Follow-up abdominal healthy patient with persistent vomiting who was sequen- magnetic resonance imaging (Figure 1) demonstrated an tially diagnosed with peptic ulcer disease (PUD), pancreati- infiltrating duodenal mass with a resultant high-grade GOO. tis, and cholecystitis. Unfortunately, the diagnostic workup Histological examination from repeat endoscopic biopsies of was less straightforward than initially suspected, as she was the duodenal mass revealed signet ring cells infiltrating the eventually diagnosed with a malignant GOO. lamina propria with positive estrogen and progesterone To the
    [Show full text]
  • A Case Report of Benign Granulosa Cells Within the Fallopian Tube
    A Case Report of Benign Granulosa Cells within the Fallopian Tube Mimicking Malignancy Granulosa cells are ovarian, sex-cord stromal derived cells which surround and support the developing follicle. Foci of extra-follicular granulosa cells have been rarely reported and may represent a significant diagnostic challenge and potential pitfall, especially in the setting of a previous history of malignancy. Here we present a case of benign, displaced granulosa cells within the fallopian tube mimicking malignancy. A 39 year old female with a history of pancreatic gastrinoma and node-positive lobular breast carcinoma was scheduled for total abdominal hysterectomy and bilateral salpingectomy for abnormal uterine bleeding; intraoperative discovery of bilateral ovarian cysts prompted the inclusion of a bilateral cystectomy, in addition to the planned procedure. Gross examination of the submitted specimens demonstrated only uterine leiomyomata, fragments of thickened ovarian cyst wall with a small amount of normal, attached ovary and no remarkable findings associated with the fallopian tubes. Microscopic examination confirmed the gross findings of uterine leiomyomata and ovarian corpora lutea cysts. Additionally, a small (1mm) focus of monomorphic, polygonal-shaped cells with scattered, mildly grooved nuclei and coincident glandular structures filled with eosinophilic material, suggesting Call-Exner bodies, was present within the right fallopian tubal stroma, reaching to the surface epithelium. Given these findings and the patient’s significant history of malignancy, our differential included granulosa cell tumor, metastatic lobular carcinoma of the breast, neuroendocrine tumor and displaced benign granulosa cells. Subsequent immunohistochemical staining supported a diagnosis of displaced, benign granulosa cells. The cells stained positively for inhibin and pancytokeratin (Lu-5) in a dot-like pattern, consistent with granulosa cells, while staining negative for CD56, CK7, synaptophysin and chromogranin, consistent with a diagnosis of benign, displaced granulosa cells.
    [Show full text]